G. Walmsley Graham - 25 Mar 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 25 Mar 2025
Net transactions value: +$8,787,921
Form type: 4
Filing time: 27 Mar 2025, 19:42:13 UTC
Previous filing: 07 Feb 2025
Next filing: 05 Jun 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Purchase	$4,085,804	+91,309	+9.1%	$44.75	1,091,309	25 Mar 2025	See Footnote 1	F1
transaction	AKRO	Common Stock	Purchase	$2,524,417	+58,691	+5.4%	$43.01	1,150,000	26 Mar 2025	See Footnote 1	F1
transaction	AKRO	Common Stock	Purchase	$2,177,700	+50,000	+4.3%	$43.55	1,200,000	27 Mar 2025	See Footnote 1	F1
holding	AKRO	Common Stock						2,168	25 Mar 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Content

The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.